Xeris Biopharma Holdings Inc. has outlined a strategic roadmap aimed at achieving long-term growth and value creation. The company plans to leverage its financial strength for self-funding both near- and long-term growth, driven by rapid revenue growth and disciplined capital management. A key component of this strategy is the anticipated revenue acceleration of Recorlev®, which is expected to mark a pivotal growth phase. Xeris has set a 2025 revenue target between $260 million and $275 million, with intentions to remain adjusted EBITDA positive. Looking further ahead, the company projects total revenue to reach approximately $750 million by 2030, led by Recorlev®. By 2035, Recorlev® is anticipated to achieve annual net revenue of approximately $1 billion, while XP-8121 is expected to reach peak net revenue of $1 to $3 billion. These projections are part of Xeris's commitment to delivering innovative solutions and addressing unmet medical needs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。